GWM
AXSM icon

Geneos Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Geneos Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16
Closed -$1.94K – 2467
2025
Q3 		$1.94K Sell
16
-34
-68% -$3.83K ﹤0.01% 2323
2025
Q2 		$5.22K Buy
50
+27
+117% +$2.86K ﹤0.01% 2561
2025
Q1 		$2.68K Hold
23
– – ﹤0.01% 2688
2024
Q4 		$1.95K Hold
23
– – ﹤0.01% 2601
2024
Q3 		$2.07K Buy
+23
New +$2.01K ﹤0.01% 2292
2020
Q1 		– Sell
-2,406
Closed -$245K – 2477
2019
Q4 		$245K Buy
+2,406
New +$97.2K 0.01% 617

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geneos Wealth Management's AXSM Position: Q4 2025 in Review

Geneos Wealth Management sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 16 shares — an estimated $1.94K sold.

Geneos Wealth Management first reported a position in AXSM in Q4 2019 and held it in 6 quarters. The position peaked at $245K in Q4 2019. 399 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

  • Geneos Wealth Management reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 16 Axsome Therapeutics shares in Q4 2025, an estimated $1.94K.
  • Geneos Wealth Management first reported a position in Axsome Therapeutics in Q4 2019 and held it in 6 quarters.
  • Geneos Wealth Management's Axsome Therapeutics position peaked at $245K in Q4 2019.
  • 399 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on Geneos Wealth Management's 13F filing for Q4 2025, filed 28 Jan 2026.